[1]
|
Chen,W.Q., Zheng, R.S., Baade, P.D., et al. (2016) Cancer Statistics in China, 2015. CA: A Cancer Journal for Clinicians, 66, 115-132. https://doi.org/10.3322/caac.21338
|
[2]
|
Lobo, N., Mount, C., Omar, K., Nair, R., Thurairaja, R. and Khan, M.S. (2017) Landmarks in the Treatment of Muscle-Invasive Bladder Cancer. Nature Reviews Urology, 14, 565-574.
|
[3]
|
Schmierer, B. and Hill, C.S. (2007) Tgfβ-SMAD Signal Transduction: Molecular Specificity and Functional Flexibility. Nature Reviews Molecular Cell Biology, 8, 970-982. https://doi.org/10.1038/nrm2297
|
[4]
|
Morikawa, M., Derynck, R. and Miyazono, K. (2016) TGF-β and the TGF-β Family: Context-Dependent Roles in Cell and Tissue Physiology. Cold Spring Harbor Perspectives in Biology, 8, A021873.
https://doi.org/10.1101/cshperspect.a021873
|
[5]
|
Harradine, K.A. and Akhurst, R.J. (20096) Mutations of Tgfβ Signaling Molecules in Human Disease. Annals of Medicine, 38, 403-414. https://doi.org/10.1080/07853890600919911
|
[6]
|
Gomis, R.R., Alarcón, C., He, W., et al. (2006) A Foxo-Smad Synexpression Group in Human Keratinocytes. Proc Proceedings of the National Academy of Sciences of the United States of America, 103, 12747-12752.
https://doi.org/10.1073/pnas.0605333103
|
[7]
|
Li, W., Kidiyoor, A., Hu, Y.Y., et al. (2015) Evaluation of Transforming Growth Factor-β1 Suppress Pokemon or Epithelial-Mesenchymal Transition Expression in Human Bladder Cancer Cells. Tumor Biology, 36, 1155-1162.
https://doi.org/10.1007/s13277-014-2625-2
|
[8]
|
Eder, I.E., Stenzl, A., Hobisch, A., Cronauer, M.V., Bartsch, G. and Klocker, H. (1996) Transforming Growth Factors-Beta 1 and Beta 2 in Serum and Urine from Patients with Bladder Carcinoma. Journal of Urology, 156, 953-957.
https://doi.org/10.1016/S0022-5347(01)65670-2
|
[9]
|
Smith, A.L., Iwanaga, R., Drasin, D.J., et al. (2012) The miR-106b-25 Cluster Targets Smad7, Activates TGF-β Signaling, and Induces EMT and Tumor Initiating Cell Characteristics Downstream of Six1 in Human Breast Cancer. Oncogene, 31, 5162-5171. https://doi.org/10.1038/onc.2012.11
|
[10]
|
Waerner, T., Alacakaptan, M., Tamir, I., et al. (2006) ILEI: A Cytokine Essential for EMT, Tumor Formation, and Late Events in Metastasis in Epithelial Cells. Cancer Cell, 10, 227-239. https://doi.org/10.1016/j.ccr.2006.07.020
|
[11]
|
Nollet, F., Kools, P. and Van Roy, F. (2000) Phylogenetic Analysis of the Cadherin Superfamily Allows Identification of Six Major Subfamilies besides Several Solitary Members. Journal of Molecular Biology, 299, 551-572.
https://doi.org/10.1006/jmbi.2000.3777
|
[12]
|
Chaw, S.Y., Abdul Majeed, A., Dalley, A.J., Chan, A., Stein, S. and Farah, C.S. (2012) Epithelial to Mesenchymal Transition (EMT) Biomarkers—E-Cadherin, Beta-Catenin, APC and Vimentin—In Oral Squamous Cell Carcinogenesis and Transformation. Oral Oncology, 48, 997-1006. https://doi.org/10.1016/j.oraloncology.2012.05.011
|
[13]
|
Froeling, F.E., Mirza, T.A., Feakins, R.M., et al. (2009) Organotypic Culture Model of Pancreatic Cancer Demonstrates That Stromal Cells Modulate E-Cadherin, β-Catenin, and Ezrin Expression in Tumor Cells. The American Journal of Pathology, 175, 636-648. https://doi.org/10.2353/ajpath.2009.090131
|
[14]
|
De Wever, O., Pauwels, P., De Craene, B., et al. (2008) Molecular and Pathological Signatures of Epithelial-Mesenchymal Transitions at the Cancer Invasion Front. Histochemistry and Cell Biology, 130, 481-494.
https://doi.org/10.1007/s00418-008-0464-1
|
[15]
|
Yilmaz, M. and Christofori, G. (2009) EMT, the Cytoskeleton, and Cancer Cell Invasion. Cancer and Metastasis Reviews, 28, 15-33. https://doi.org/10.1007/s10555-008-9169-0
|
[16]
|
Van Der Horst, G., Bos, L. and Van Der Pluijm, G. (2012) Epithelial Plasticity, Cancer Stem Cells, and the Tumor-Supportive Stroma in Bladder Carcinoma. Molecular Cancer Research, 10, 995-1009.
https://doi.org/10.1158/1541-7786.MCR-12-0274
|
[17]
|
Thuault, S., Tan, E.J., Peinado, H., Cano, A., Heldin, C.H. and Moustakas, A. (2008) HMGA2 and Smads Co-Regulate SNAIL1 Expression during Induction of Epithelial-To-Mesenchymal Transition. The Journal of Biological Chemistry, 283, 33437-33446. https://doi.org/10.1074/jbc.M802016200
|
[18]
|
闫鹏, 达林泰, 德乐黑巴特尔. TGF-β/Smad信号通路在恶性肿瘤作用及基理研究进展[J]. 内蒙古医科大学学报, 2018, 40(5): 541-544.
|
[19]
|
Shimizu, J., Izumi, T., Arimitsu, N., et al. (2012) Skewed TGFβ/Smad Signalling Pathway in T Cells in Patients with Behçet’s Disease. Clinical and Experimental Rheumatology, 30, S35-S39.
|
[20]
|
Lee, J.J., Chang, Y.L., Lai, W.L., et al. (2011) Increased Prevalence of Interleukin-17-Producing CD4+ Tumor Infiltrating Lymphocytes in Human Oral Squamous Cell Carcinoma. Head & Neck, 33, 1301-1308.
https://doi.org/10.1002/hed.21607
|
[21]
|
Letterio, J.J. and Roberts, A.B. (1998) Regulation of Immune Responses by TGF-β. Annual Review of Immunology, 16, 137-161. https://doi.org/10.1146/annurev.immunol.16.1.137
|
[22]
|
Chu, T.H., Yang, C.C., Liu, C.J., Lui, M.T., Lin, S.C. and Chang, K.W. (2013) MiR-211 Promotes the Progression of Head and Neck Carcinomas by Targeting TGFβRII. Cancer Letters, 337, 115-124.
https://doi.org/10.1016/j.canlet.2013.05.032
|
[23]
|
Topalian, S.L., Taube, J.M., Anders, R.A. and Pardoll, D.M. (2016) Mechanism-Driven Biomarkers to Guide Immune Checkpoint Blockade in Cancer Therapy. Nature Reviews Cancer, 16, 275-287. https://doi.org/10.1038/nrc.2016.36
|
[24]
|
Sharpe, A.H., Wherry, E.J., Ahmed, R. and Freeman, G.J. (2007) The Function of Programmed Cell Death 1 and Its Ligands in Regulating Autoimmunity and Infection. Nature Immunology, 8, 239-245. https://doi.org/10.1038/ni1443
|
[25]
|
Garrido, F., Cabrera, T., Concha, A., Glew, S., Ruiz-Cabello, F. and Stern, P.L. (1993) Natural History of HLA Expression during Tumour Development. Immunology Today, 14, 491-499.
https://doi.org/10.1016/0167-5699(93)90264-L
|
[26]
|
Muenst, S., Schaerli, A.R., Gao, F., et al. (2014) Expression of Programmed Death Ligand 1 (PD-L1) Is Associated with Poor Prognosis in Human Breast Cancer. Breast Cancer Research and Treatment, 146, 15-24.
https://doi.org/10.1007/s10549-014-2988-5
|
[27]
|
Taube, J.M., Anders, R.A., Young, G.D., et al. (2012) Colocalization of Inflammatory Response with B7-H1 Expression in Human Melanocytic Lesions Supports an Adaptive Resistance Mechanism of Immune Escape. Science Translational Medicine, 4, 127ra37. https://doi.org/10.1126/scitranslmed.3003689
|
[28]
|
Liu, J.Z., Hamrouni, A., Wolowiec, D., et al. (2007) Plasma Cells from Multiple Myeloma Patients Express B7-H1 (PD-L1) and Increase Expression after Stimulation with IFN-γ and TLR Ligands via a Myd88-, TRAF6-, and MEK-Dependent Pathway. Blood, 110, 296-304. https://doi.org/10.1182/blood-2006-10-051482
|
[29]
|
Bellmunt, J., Powles, T. and Vogelzang, N.J. (2017) A Review on the Evolution of PD-1/PD-L1 Immunotherapy for Bladder Cancer: the Future Is Now. Cancer Treatment Reviews, 54, 58-67.
https://doi.org/10.1016/j.ctrv.2017.01.007
|
[30]
|
Lin, Z., Xu, Y., Zhang, Y., et al. (2016) The Prevalence and Clinicopathological Features of Programmed Death-Ligand 1 (PD-L1) Expression: A Pooled Analysis of Literatures. Oncotarget, 7, 15033-15046.
https://doi.org/10.18632/oncotarget.7590
|
[31]
|
Nakanishi, J., Wada, Y., Matsumoto, K., Azuma, M., Kikuchi, K. and Ueda, S. (2007) Overexpression of B7-H1 (PD-L1) Significantly Associates with Tumor Grade and Postoperative Prognosis in Human Urothelial Cancers. Cancer Immunology, Immunotherapy, 56, 1173-1182. https://doi.org/10.1007/s00262-006-0266-z
|
[32]
|
Khong, H.T., Wang, Q.J. and Rosenberg, S.A. (2004) Identification of Multiple Antigens Recognized by Tumor-Infiltrating Lymphocytes from a Single Patient: Tumor Escape by Antigen Loss and Loss of MHC Expression. Journal of Immunotherapy, 27, 184-190. https://doi.org/10.1097/00002371-200405000-00002
|
[33]
|
Rosenberg, S.A. (2001) Progress in Human Tumour Immunology and Immunotherapy. Nature, 411, 380-384.
https://doi.org/10.1038/35077246
|
[34]
|
Powles, T., Eder, J.P., Fine, G.D., et al. (2014) MPDL3280A (Anti-PD-L1) Treatment Leads to Clinical Activity in Metastatic Bladder Cancer. Nature, 515, 558-562. https://doi.org/10.1038/nature13904
|
[35]
|
Flies, D.B. and Chen, L. (2007) The New B7s: Playing A Pivotal Role in Tumor Immunity. Journal of Immunotherapy, 30, 251-260. https://doi.org/10.1097/CJI.0b013e31802e085a
|
[36]
|
Liu, L., Liu, X., Ren, X., et al. (2016) Smad2 and Smad3 Have Differential Sensitivity in Relaying TGFβ Signaling and Inversely Regulate Early Lineage Specification. Scientific Reports, 6, Article ID: 21602.
https://doi.org/10.1038/srep21602
|
[37]
|
Sun, X., Cui, Y., Feng, H., Liu, H. and Liu, X. (2019) TGF-β Signaling Controls Foxp3 Methylation and T Reg Cell Differentiation by Modulating Uhrf1 Activity. Journal of Experimental Medicine, 216, 2819-2837.
https://doi.org/10.1084/jem.20190550
|
[38]
|
Liu, M., Li, S. and Li, M.O. (2018) TGF-β Control of Adaptive Immune Tolerance: A Break from Treg Cells. BioEssays, 40, Article ID: 1800063. https://doi.org/10.1002/bies.201800063
|
[39]
|
Cohen, N., Mouly, E., Hamdi, H., et al. (2006) GILZ Expression in Human Dendritic Cells Redirects Their Maturation and Prevents Antigen-Specific T Lymphocyte Response. Blood, 107, 2037-2044.
https://doi.org/10.1182/blood-2005-07-2760
|
[40]
|
Francisco, L.M., Salinas, V.H., Brown, K.E., et al. (2009) PD-L1 Regulates the Development, Maintenance, and Function of Induced Regulatory T Cells. Journal of Experimental Medicine, 206, 3015-3029.
https://doi.org/10.1084/jem.20090847
|